APP receives FDA approval to market Gemcitabine HCI for Injection, USP in 2 g dosage APP Pharmaceuticals, Inc prescription drugs online ., a owned subsidiary of Fresenius Kabi Pharmaceuticals Keeping wholly, Inc., announced today that it has received approval from the U.S. Food and Medication Administration to advertise Gemcitabine HCI for Injection, USP, in the 2 2 g dosage strength. APP will start this demonstration of Gemcitabine immediately. In January 2011, Teva Pharmaceuticals USA, Inc. Received authorization and APP Pharmaceuticals launched Gemcitabine HCI for Injection in the 200 mg and 1g dosage forms as part of a commercialization, supply and manufacture agreement with Teva. According to IMS Wellness data, 2010 branded revenue of all dosage strengths of Gemcitabine HCI for Injection in the United States were around $780 million.
Predicated on the Foundation’s Project IMPACT: Diabetes, Diabetes Ten Town Challenge, and Patient-Self Administration Plan for Diabetes, the PSM Solutions model includes the Patient Self-Management Credential for Diabetes, APhA Basis’s groundbreaking software program, a national network of pharmacist companies, and the methodology refined over the course of the Base’s analysis. With the flexibility to include the PSMC for Diabetes to an existing program or develop an end-to-end comprehensive option, PSM Solutions are ideally fitted to innovative employers and wellness plans looking to effectively address their chronic disease management requirements.